An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

Name: An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
Published: 2023
License: Public Domain

Servier Affaires Médicales · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

acute myeloid leukemia (aml), idh1 mutation aml, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

Related documents